Abstract
We assessed the impact of loiasis and its treatment with ivermectin on hemostasis and inflammation in 38 adults in Cameroon. Participants were divided into four balanced groups based on their Loa loa microfilarial densities. At baseline, a positive correlation was observed between microfilarial densities, neutrophils (p=0.012) and eosinophils (p<0.001). At day 4 following ivermectin administration, mean D-dimers significantly increased, from 725 ng/mL to 1,276 ng/mL (p=0.024). Mean eosinophils rose from 225/µL to 1,807/µL (p<0.001). C-reactive protein, fibrinogen, and alpha-1-globulin also increased significantly after treatment. Ivermectin treatment appeared to induce inflammation and pronounced fibrinolysis, indicative of coagulation activation.
Competing Interest Statement
The authors declare that they have no competing interests.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study adhered to ethical guidelines outlined in the Declaration of Helsinki, version 13, and was approved by the Ethics Committee for Human Research of the Catholic University of Central Africa (N° 2022/022503/CEIRSH/ESS/MH) and by Yaoundé University Teaching Hospital (N°4181/AR/CHUY/DG/DGA/CAPRC). Only individuals who provided informed consent were enrolled and assigned an individual code for data recording. Blood parameters results were shared with all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Anonymized data will be hosted on the server https://dataverse.ird.fr/, and the terms of use will be those in force on the hosting site.
